Vericel Corp Ord (VCEL) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.
Total Assets Chart for Vericel Corp Ord
Vericel Corp Ord (VCEL) total assets for FY2025 were USD 488.0M, a 12.8% change from FY2024. Vericel Corp Ord's total assets grew from USD 6.1M in 1995 to USD 488.0M in 2025 (7899.5% over 30 years). Total assets compound annual growth rate: 5-year CAGR of 18.9%, 10-year CAGR of 30.4%, 20-year CAGR of 14.3%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $2.18B
- Implied Share Price
- $42.53
- Enterprise Value
- $2.28B
- Revenue (TTM)
- $306.30M
- EBITDA
- $31.15M
- Profit Margin
- 7.91%
- Trailing P/E
- 90.49
- Forward P/E
- 97.09
- Price/Book (MRQ)
- 6.36
- Price/Sales (TTM)
- 7.11
- EV/EBITDA
- 59.10
- EV/Revenue
- 7.46
- Dividend Yield
- —
- Book Value
- $7.23
- Free Cash Flow (FY2025)
- $24.75M
- Free Cash Flow Yield
- 1.14%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.